{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T06:24:08Z","timestamp":1787293448239,"version":"build-2736575974"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Bioeng. Biotechnol."],"abstract":"<jats:p>The efficiency of cell culture-based vaccine production is fundamentally constrained by the antiviral defenses of host cells, creating a major bottleneck for rapid and large-scale vaccine manufacturing. Key antiviral proteins-such as RNase L, PKR, and JAK1 act as intrinsic brakes on viral replication, limiting efficient propagation of many clinically relevant viruses. To overcome this challenge, we generated HEK293T, Vero, and MDCK cell lines with targeted knockouts of multiple antiviral genes. Notably, these engineered cells maintained normal growth and viability while supporting markedly increased viral yields. Multi-gene deletions enhance the replication of both enveloped viruses, including influenza A virus, pseudotyped lentivirus, and porcine epidemic diarrhea virus (PEDV), and non-enveloped viruses such as coxsackievirus. The magnitude of enhancement scaled proportionally with the number of genes disrupted. By systematically removing host restriction factors, this platform provides a versatile and powerful strategy for accelerating viral propagation, offering a strong foundation for more efficient development and large-scale production of cell culture-based anti-viral vaccines.<\/jats:p>","DOI":"10.3389\/fbioe.2026.1877497","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:35:54Z","timestamp":1787290554000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic removal of host restriction factors enables rapid, scalable virus production for cell culture-based vaccine development"],"prefix":"10.3389","volume":"14","author":[{"given":"Zhengmei","family":"Xu","sequence":"first","affiliation":[{"name":"Division of Life Sciences, College of Life Sciences and Biotechnology, Korea University","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaemyeong","family":"Jeon","sequence":"additional","affiliation":[{"name":"Division of Life Sciences, College of Life Sciences and Biotechnology, Korea University","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsoo","family":"Oh","sequence":"additional","affiliation":[{"name":"Division of Life Sciences, College of Life Sciences and Biotechnology, Korea University","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngki","family":"Shin","sequence":"additional","affiliation":[{"name":"Division of Life Sciences, College of Life Sciences and Biotechnology, Korea University","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se-Ho","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Life Sciences, College of Life Sciences and Biotechnology, Korea University","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"B33","doi-asserted-by":"publisher","first-page":"e23931","DOI":"10.4161\/jkst.23931","article-title":"Transcriptional regulation by STAT1 and STAT2 in the interferon JAK-STAT pathway","volume":"2","author":"Au-Yeung","year":"2013","journal-title":"Jakstat"},{"key":"B1","doi-asserted-by":"publisher","first-page":"106634","DOI":"10.1016\/j.isci.2023.106634","article-title":"Cell culture systems for isolation of SARS-CoV-2 clinical isolates and generation of recombinant virus","volume":"26","author":"Chen","year":"2023","journal-title":"iScience"},{"key":"B2","doi-asserted-by":"publisher","first-page":"16904","DOI":"10.1021\/acsomega.3c10484","article-title":"Animal cell lines as expression platforms in viral Vaccine production: a post Covid-19 perspective","volume":"9","author":"Demirden","year":"2024","journal-title":"ACS Omega"},{"key":"B3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nrmicro817","article-title":"Virus entry: molecular mechanisms and biomedical applications","volume":"2","author":"Dimitrov","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/nri3295","article-title":"Evolutionary conflicts between viruses and restriction factors shape immunity","volume":"12","author":"Duggal","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.tim.2010.06.010","article-title":"BST-2\/tetherin: a new component of the innate immune response to enveloped viruses","volume":"18","author":"Evans","year":"2010","journal-title":"Trends Microbiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/epirev\/mxz014","article-title":"Postexposure effects of Vaccines on infectious diseases","volume":"41","author":"Gallagher","year":"2019","journal-title":"Epidemiol. Rev."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1128\/mmbr.00027-06","article-title":"Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action","volume":"70","author":"Garc\u00eda","year":"2006","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/biot.201400388","article-title":"Designing cell lines for viral vaccine production: where do we stand?","volume":"10","author":"Genzel","year":"2015","journal-title":"Biotechnol. J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1080\/21645515.2015.1016666","article-title":"Cell culture-based influenza vaccines: a necessary and indispensable investment for the future","volume":"11","author":"Hegde","year":"2015","journal-title":"Hum. Vaccin Immunother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1408510","DOI":"10.3389\/fimmu.2024.1408510","article-title":"Development of a live attenuated vaccine candidate for equid alphaherpesvirus 1 control: a step towards efficient protection","volume":"15","author":"Hu","year":"2024","journal-title":"Front. Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/bit.28553","article-title":"Accelerated and intensified manufacturing of an adenovirus-vectored vaccine to enable rapid outbreak response","volume":"121","author":"Joe","year":"2024","journal-title":"Biotechnol. Bioeng."},{"key":"B37","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1099\/jgv.0.001603","article-title":"Discovering antiviral restriction factors and pathways using genetic screens","volume":"102","author":"Jones","year":"2021","journal-title":"Gen. Virol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"102636","DOI":"10.1016\/j.omtn.2025.102636","article-title":"Off-target effects in CRISPR-Cas genome editing for human therapeutics: progress and challenges","volume":"36","author":"Kalter","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B10","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.chom.2016.08.005","article-title":"Identification of interferon-stimulated genes with antiretroviral activity","volume":"20","author":"Kane","year":"2016","journal-title":"Cell Host Microbe"},{"key":"B11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41541-022-00447-3","article-title":"Pandemic-response adenoviral vector and RNA vaccine manufacturing","volume":"7","author":"Kis","year":"2022","journal-title":"NPJ Vaccines"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.3389\/fmicb.2019.01634","article-title":"Modeling Varicella zoster virus persistence and reactivation - closer to resolving a perplexing persistent state","volume":"10","author":"Laemmle","year":"2019","journal-title":"Front. Microbiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3390\/v3050520","article-title":"Antiviral inhibition of enveloped virus release by tetherin\/BST-2: action and counteraction","volume":"3","author":"Le Tortorec","year":"2011","journal-title":"Viruses"},{"key":"B13","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/1743-422x-10-250","article-title":"Establishment of cell lines with increased susceptibility to EV71\/CA16 by stable overexpression of SCARB2","volume":"10","author":"Li","year":"2013","journal-title":"Virol. J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3390\/vaccines13070730","article-title":"Research progress on varicella-zoster virus vaccines","volume":"13","author":"Liu","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"7864","DOI":"10.1128\/jvi.00869-16","article-title":"Opposing roles of double-stranded RNA effector pathways and viral defense proteins revealed with CRISPR-Cas9 knockout cell lines and vaccinia virus mutants","volume":"90","author":"Liu","year":"2016","journal-title":"J. Virol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"107113","DOI":"10.1016\/j.nbd.2025.107113","article-title":"PKR-driven ISR signaling controls synaptic translation and structural plasticity in an age-dependent manner","volume":"216","author":"Mart\u00ednez","year":"2025","journal-title":"Neurobiol. Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.ymthe.2022.05.018","article-title":"Precision medicine: in vivo CAR therapy as a showcase for receptor-targeted vector platforms","volume":"30","author":"Michels","year":"2022","journal-title":"Mol. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"106699","DOI":"10.1016\/j.phrs.2023.106699","article-title":"Meeting vaccine formulation challenges in an emergency setting: towards the development of accessible vaccines","volume":"189","author":"Peletta","year":"2023","journal-title":"Pharmacol. Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1099\/vir.0.83391-0","article-title":"Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures","volume":"89","author":"Randall","year":"2008","journal-title":"J. Gen. Virol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e1000311","DOI":"10.1371\/journal.ppat.1000311","article-title":"An antiviral response directed by PKR phosphorylation of the RNA helicase A","volume":"5","author":"Sadler","year":"2009","journal-title":"PLoS Pathog."},{"key":"B30","doi-asserted-by":"publisher","first-page":"12720","DOI":"10.1128\/jvi.01471-07","article-title":"Viral encounters with 2',5'-oligoadenylate synthetase and RNase L during the interferon antiviral response","volume":"81","author":"Silverman","year":"2007","journal-title":"J. Virol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e1004360","DOI":"10.1371\/journal.ppat.1004360","article-title":"Delineation of interfaces on human alpha-defensins critical for human adenovirus and human papillomavirus inhibition","volume":"10","author":"Tenge","year":"2014","journal-title":"PLoS Pathog."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e2215600119","DOI":"10.1073\/pnas.2215600119","article-title":"Enveloped viruses show increased propensity to cross-species transmission and zoonosis","volume":"119","author":"Valero-Rello","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.chom.2008.03.001","article-title":"The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein","volume":"3","author":"Van Damme","year":"2008","journal-title":"Cell Host Microbe"},{"key":"B19","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41541-023-00773-0","article-title":"Outlook of pandemic preparedness in a post-COVID-19 world","volume":"8","author":"Williams","year":"2023","journal-title":"NPJ Vaccines"},{"key":"B20","doi-asserted-by":"publisher","first-page":"11370","DOI":"10.1093\/nar\/gkaa930","article-title":"Benchmarking and integrating genome-wide CRISPR off-target detection and prediction","volume":"48","author":"Yan","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13568-019-0794-5","article-title":"Large-scale microcarrier culture of HEK293T cells and vero cells in single-use bioreactors","volume":"9","author":"Yang","year":"2019","journal-title":"Amb. Express"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1002\/bit.26338","article-title":"Enhanced production of enveloped viruses in BST-2-deficient cell lines","volume":"114","author":"Yi","year":"2017","journal-title":"Biotechnol. Bioeng."},{"key":"B23","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.bbrc.2018.12.110","article-title":"BST2 inhibits infection of influenza A virus by promoting apoptosis of infected cells","volume":"509","author":"Yi","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2373521","DOI":"10.1080\/21645515.2024.2373521","article-title":"Innovations in cell culture-based influenza vaccine manufacturing - from static cultures to high cell density cultivations","volume":"20","author":"Zinnecker","year":"2024","journal-title":"Hum. Vaccin Immunother."}],"container-title":["Frontiers in Bioengineering and Biotechnology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2026.1877497\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:35:55Z","timestamp":1787290555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2026.1877497\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":37,"alternative-id":["10.3389\/fbioe.2026.1877497"],"URL":"https:\/\/doi.org\/10.3389\/fbioe.2026.1877497","relation":{},"ISSN":["2296-4185"],"issn-type":[{"value":"2296-4185","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"article-number":"1877497"}}